Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125454172 | 12545417 | 2 | F | 20160621 | 20160725 | 20160711 | 20160728 | EXP | CH-009507513-1607CHE002485 | MERCK | 74.00 | YR | M | Y | 0.00000 | 20160728 | CN | US | CH |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125454172 | 12545417 | 1 | PS | TEMOZOLOMIDE. | TEMOZOLOMIDE | 1 | Oral | 150 MG/M2, ON DAYS 1-5 OF 28 DAYS CYCLE | 21029 | 150 | MG/M**2 | CAPSULE | |||||||
| 125454172 | 12545417 | 2 | SS | ABT-414 | INVESTIGATIONAL PRODUCT | 1 | Intravenous (not otherwise specified) | 1 MG/KG, 1 IN 2 WEEKS (QOW) | 2 | MG/KG | 0 | 1 | MG/KG | QOW | |||||
| 125454172 | 12545417 | 3 | C | AVAMYS | FLUTICASONE FUROATE | 1 | Nasal | 2 DF, QD | U | 0 | 2 | DF | QD | ||||||
| 125454172 | 12545417 | 4 | C | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Oral | 800/160 (0.5 TABLET, QD) | U | 0 | .5 | DF | TABLET | QD | |||||
| 125454172 | 12545417 | 5 | C | BELOC-ZOK | METOPROLOL SUCCINATE | 1 | Oral | 25 MG, QD | U | 0 | 25 | MG | QD | ||||||
| 125454172 | 12545417 | 6 | C | BELOC-ZOK | METOPROLOL SUCCINATE | 1 | U | 0 | |||||||||||
| 125454172 | 12545417 | 7 | C | COSOPT | DORZOLAMIDE HYDROCHLORIDETIMOLOL MALEATE | 1 | Ophthalmic | 1 DROP, BID, IN LEFT EYE | U | 0 | 1 | GTT | BID | ||||||
| 125454172 | 12545417 | 8 | C | DAFALGAN | ACETAMINOPHEN | 1 | Oral | DAILY DOSE: 1000 MG, PRN | U | 0 | TID | ||||||||
| 125454172 | 12545417 | 9 | C | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 4 MG, QD | 356 | MG | U | 0 | 4 | MG | TABLET | QD | |||
| 125454172 | 12545417 | 10 | C | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 3 MG, QD | 356 | MG | U | 0 | 3 | MG | TABLET | QD | |||
| 125454172 | 12545417 | 11 | C | IMPORTAL | LACTITOL | 1 | Oral | 10 ML, QD, AS REQUIRED (PRN) | U | 0 | |||||||||
| 125454172 | 12545417 | 12 | C | IMPORTAL | LACTITOL | 1 | Oral | 20 ML, TID | U | 0 | 20 | ML | TID | ||||||
| 125454172 | 12545417 | 13 | C | KEPPRA | LEVETIRACETAM | 1 | Oral | 500 MG, BID | U | 0 | 500 | MG | BID | ||||||
| 125454172 | 12545417 | 14 | C | KEPPRA | LEVETIRACETAM | 1 | U | 0 | |||||||||||
| 125454172 | 12545417 | 15 | C | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 40 MG, QD | U | 0 | 40 | MG | QD | ||||||
| 125454172 | 12545417 | 16 | C | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | U | 0 | |||||||||||
| 125454172 | 12545417 | 17 | C | NOVOMIX 30 | INSULIN ASPART | 1 | Subcutaneous | 26-0-14 IU | U | 0 | |||||||||
| 125454172 | 12545417 | 18 | C | QUETIAPINE FUMARATE. | QUETIAPINE FUMARATE | 1 | Oral | DAILY DOSE: 12.5 MG, QAM 25 MG, QPM | U | 0 | BID | ||||||||
| 125454172 | 12545417 | 19 | C | SIMVASTATIN. | SIMVASTATIN | 1 | Oral | 40 MG, QD | U | 0 | 40 | MG | TABLET | QD | |||||
| 125454172 | 12545417 | 20 | C | SINTROM | ACENOCOUMAROL | 1 | Oral | 1 MG, UNK, ACCORDING TO INR | U | 0 | 1 | MG | |||||||
| 125454172 | 12545417 | 21 | C | SINTROM | ACENOCOUMAROL | 1 | U | 0 | |||||||||||
| 125454172 | 12545417 | 22 | C | SINTROM | ACENOCOUMAROL | 1 | U | 0 | |||||||||||
| 125454172 | 12545417 | 23 | C | TORSEMIDE. | TORSEMIDE | 1 | Oral | 5 MG, QD | U | 0 | 5 | MG | QD | ||||||
| 125454172 | 12545417 | 24 | C | TORSEMIDE. | TORSEMIDE | 1 | Oral | 10 MG, QD | U | 0 | 10 | MG | QD | ||||||
| 125454172 | 12545417 | 25 | C | NITROGLYCERIN. | NITROGLYCERIN | 1 | Oral | TOTAL DAILY DOSE: 0.8 MG, PRN | U | 0 | |||||||||
| 125454172 | 12545417 | 26 | C | CYANOCOBALAMIN. | CYANOCOBALAMIN | 1 | Subcutaneous | 1 MG, QM | U | 0 | 1 | MG | /month | ||||||
| 125454172 | 12545417 | 27 | C | DEXAMETHASONE. | DEXAMETHASONE | 1 | Ophthalmic | 2 GTT, Q8H, EACH EYE | 42 | Gtt | U | 0 | 2 | GTT | EYE DROPS, SOLUTION | Q8H | |||
| 125454172 | 12545417 | 28 | C | DISTRANEURIN | CLOMETHIAZOLE | 1 | Oral | 192 MG, QPM | U | 0 | 192 | MG | QD | ||||||
| 125454172 | 12545417 | 29 | C | CICATREX | 2 | Topical | 1 DF, QD | U | 0 | 1 | DF | CREAM | QD | ||||||
| 125454172 | 12545417 | 30 | C | BEPANTHEN (dexpanthenol) | 2 | Topical | 1 DF, BID | U | 0 | 1 | DF | BID | |||||||
| 125454172 | 12545417 | 31 | C | EXCIPIAL EMULSION | 2 | Topical | 1 - 2 APPLICATIONS DAILY | U | 0 | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125454172 | 12545417 | 1 | Glioblastoma |
| 125454172 | 12545417 | 2 | Glioblastoma |
| 125454172 | 12545417 | 3 | Rhinitis allergic |
| 125454172 | 12545417 | 4 | Infection prophylaxis |
| 125454172 | 12545417 | 5 | Hypertension |
| 125454172 | 12545417 | 6 | Hypertensive cardiomyopathy |
| 125454172 | 12545417 | 7 | Glaucoma |
| 125454172 | 12545417 | 8 | Pain |
| 125454172 | 12545417 | 9 | Brain oedema |
| 125454172 | 12545417 | 11 | Constipation |
| 125454172 | 12545417 | 13 | Epilepsy |
| 125454172 | 12545417 | 14 | Prophylaxis |
| 125454172 | 12545417 | 15 | Gastric disorder |
| 125454172 | 12545417 | 16 | Prophylaxis |
| 125454172 | 12545417 | 17 | Diabetes mellitus |
| 125454172 | 12545417 | 18 | Adjustment disorder with depressed mood |
| 125454172 | 12545417 | 19 | Hyperlipidaemia |
| 125454172 | 12545417 | 20 | Atrial fibrillation |
| 125454172 | 12545417 | 21 | Myocardial infarction |
| 125454172 | 12545417 | 22 | Hypertensive cardiomyopathy |
| 125454172 | 12545417 | 23 | Hypertension |
| 125454172 | 12545417 | 25 | Angina pectoris |
| 125454172 | 12545417 | 26 | Vitamin B12 deficiency |
| 125454172 | 12545417 | 27 | Eye disorder |
| 125454172 | 12545417 | 28 | Anxiety |
| 125454172 | 12545417 | 29 | Skin abrasion |
| 125454172 | 12545417 | 30 | Skin abrasion |
| 125454172 | 12545417 | 31 | Dry skin |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125454172 | 12545417 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125454172 | 12545417 | Chest pain | |
| 125454172 | 12545417 | Fatigue | |
| 125454172 | 12545417 | Malignant neoplasm progression | |
| 125454172 | 12545417 | Nervous system disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125454172 | 12545417 | 1 | 20160531 | 20160604 | 0 | |
| 125454172 | 12545417 | 2 | 20160531 | 20160614 | 0 | |
| 125454172 | 12545417 | 3 | 20160321 | 0 | ||
| 125454172 | 12545417 | 4 | 20160318 | 0 | ||
| 125454172 | 12545417 | 5 | 2005 | 0 | ||
| 125454172 | 12545417 | 7 | 2005 | 0 | ||
| 125454172 | 12545417 | 8 | 201604 | 0 | ||
| 125454172 | 12545417 | 9 | 20160318 | 20160614 | 0 | |
| 125454172 | 12545417 | 10 | 20160615 | 0 | ||
| 125454172 | 12545417 | 11 | 201604 | 20160613 | 0 | |
| 125454172 | 12545417 | 12 | 20160614 | 0 | ||
| 125454172 | 12545417 | 13 | 20151112 | 0 | ||
| 125454172 | 12545417 | 15 | 201511 | 0 | ||
| 125454172 | 12545417 | 17 | 20160606 | 0 | ||
| 125454172 | 12545417 | 18 | 201604 | 0 | ||
| 125454172 | 12545417 | 19 | 2005 | 0 | ||
| 125454172 | 12545417 | 20 | 2005 | 0 | ||
| 125454172 | 12545417 | 23 | 20160324 | 0 | ||
| 125454172 | 12545417 | 24 | 201604 | 0 | ||
| 125454172 | 12545417 | 25 | 2005 | 0 | ||
| 125454172 | 12545417 | 26 | 20160424 | 0 | ||
| 125454172 | 12545417 | 27 | 20160612 | 20160618 | 0 | |
| 125454172 | 12545417 | 28 | 20160614 | 0 | ||
| 125454172 | 12545417 | 29 | 20160614 | 0 | ||
| 125454172 | 12545417 | 30 | 20160614 | 0 | ||
| 125454172 | 12545417 | 31 | 20160531 | 0 |